All News

Epcoritamab-bysp showed a 69% objective response rate and 62% complete response rate in older patients with large B-cell lymphoma who were ineligible for anthracycline-based therapy.

Health care conferences this year showcased advancements in treatments for chronic obstructive pulmonary disease and sleep apnea, discussions around health policy and economic research, and more.

Ellen Francis, PhD, discusses the benefits, challenges, and future implications of implementing earlier diabetes screening for pregnant women.

A recent Federal Order from the US Department of Agriculture aims to track, prevent, and address contaminated dairy products while public health risk remains low.

Across treatments, rozanolixizumab and batoclimab were most effective, though rozanolixizumab carried increased risk of adverse events (AEs) and serious AEs.

Symptoms associated with long COVID were less frequent in patients living with HIV.

The most-read breast cancer articles include topics on hereditary breast cancer, hormone therapy benefits, BRCA mutations, as well as treatment outcomes.

Patients with type 2 diabetes who use semaglutide have more than double the risk of severe optic nerve damage than those who don’t use the drug.

The most-read alopecia articles include topics on Janus kinase inhibitors, new therapeutic strategies, health-related quality of life measurements, potential links to the COVID-19 vaccine, and disease pathogenesis.

Since its founding in 2012, the National Association of ACOs has evolved from a group of 30 to 477 accountable care organization members covering 9.2 million beneficiary lives.

The study offers insights on how to counteract resistance to Bruton tyrosine kinase (BTK) inhibitors.

The 2023 National Health Interview Survey found that a significant portion of US adults experience post–COVID-19 condition, or long COVID, with some facing activity limitations.

The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.

Both candidates combine 2 already licensed vaccines to prevent influenza and COVID-19.

In 2024, the most-read news articles published on the website of The American Journal of Managed Care® included FDA approvals, colonoscopy guidelines, and a list of drugs facing shortages.

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis.

The top-5 most read articles on spinal muscular atrophy (SMA) span novel research in predictive biomarkers, the benefits of newborn screening, and findings that could reshape SMA as a multisystem disorder.

New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.

The top 5 most-viewed content from this year's American Thoracic Society (ATS) 2024 International Conference featured an interview with Monica Kraft, MD, ASTF, and coverage of multiple respiratory and pulmonary medicine areas.

In the final part of our interview, Alice W. Lee, PhD, MPH, highlights the importance of addressing ovarian cancer care disparities and beyond by understanding cultural and behavioral factors and adopting a more disaggregated approach to research.

This year’s top diabetes content focused on pediatric metabolic health, misconceptions about weight loss drugs, and more.

Recent analyses spotlight inequities in health care, from the financial burdens faced by employees at small firms due to higher insurance costs to disparities in data and ovarian cancer survival among racial and ethnic groups.

The Community Oncology Alliance (COA) meetings featured expert discussions around the evolving landscape of oncology care and health care reform.

Martin Dietrich, MD, PhD, discusses how the FDA-approved combination therapy is transforming care for resectable early-stage non–small cell lung cancer (NSCLC).

Patients with interstitial lung disease (ILD) experience significantly higher rates of fatigue and excessive daytime sleepiness than healthy individuals.

Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using combinations based in immune checkpoint inhibitors.

The mean body mass index (BMI) and the prevalence of obesity both dropped in 2023 for the first time in more than a decade.

The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.